Clinical Characteristics for Predicting Recurrency in Giant Cell Tumor of Bone


  • Aisyah Ameliah Department of Pathology Anatomy, Hasanuddin University, Makassar, Indonesia
  • Upik A. Miskad Department of Pathology Anatomy, Hasanuddin University, Makassar, Indonesia
  • Muhammad P. Johan Department of Orthopedic and Traumatology, Faculty of Medicine, University of Hasanuddin, Makassar, Indonesia
  • Ni Ketut Sungowati Department of Pathology Anatomy, Hasanuddin University, Makassar, Indonesia
  • Andi A. Zainuddin Department of Public Health, Hasanuddin University, Makassar, Indonesia
  • Djumadi Achmad Department of Pathology Anatomy, Hasanuddin University, Makassar, Indonesia


GCTB, recurrency, giant cell tumor of bone, clinical characteristics


Giant Cell Tumor of Bone is classified as benign tumor with unpredictable biological behaviour. Recurrency and metastasis of GCTB could be found in this benign tumor. Many studies reported risk factor for recurrency of GCTB. This study is aimed to determine clinical factors for predict the recurrency in the giant cell tumour of the bone (GCTB). We collected clinical data of GCTB, included age, gender, location of tumor, radiographic, histopathological examination, then we classified GCTB samples into 3 groups, primary, recurrent, and metastatic based on the clinical and histopathological examination. From 52 samples, there were 34 samples of primary GCTB, 7 samples of recurrent GCTB or 13,5%, and 11 samples of GCTB metastatic or 21,1% from all samples GCTB. The incidens of recurrency was higher when the tumor destructed the cortex (Campanacci Grade 3), the location was in manus, and the intervention was curretage. There was a statistical significant difference recurrency between tumor location in manus and other locations (p<0,05). Also, there was siginificant difference recurrency between wide excision and curretage (p<0,05). We concluded that the clinical characteristics that could be predictors for recurrency are tumor location and method of surgery.


. Lin, F., et al., “The epidemiological and clinical features of primary giant cell tumor of bone around the knee: A report from the multicenter”. Journal of Bone Oncology, vol. 5, pp.38–42. 2016.

. M. A. Siddiqui, C. Seng, & M.H Tang,“Risk factors for recurrence of giant cell tumours of bone.”Journal of Orthopaedic Surgery, vol. 22, no.1, pp.108-110. 2014.

. M.H. Zheng, et al., “The histogenesis of giant cell tumour of bone: a model of interaction between neoplastic cells and osteoclasts”. Histol and Histopathol, vol.16, no.1,pp. 297-307, 2001.

. K. Gunasegaran, M.N.S.B. Irawan, A. Yantiasetiasti, “Epidemiology of Giant Cell Tumor in Dr. Hasan Sadikin General Hospital Bandung from 2010-2013.” Althea Medical Journal, vol. 3, no.2, pp.244-47, 2016.

. D.M. Fletcher, J. A. B., Pancras C.W. Hogendoorn, F. Mertens. WHO Classification of Tumours of Soft Tissue and Bone (4 ed.). France: International Agency for Research on Cancer. 2013. pp. 319–22

. M. Werner. “Giant cell tumor of bone: morphological, biological, and histogenetical aspects”. International Orthopaedics, vol.30, pp. 484-9, 2006.

. B. J. Noh, & Y. K. Park, “Giant cell tumor of bone of bone: updated molecular pathogenesis and tumor biology.” Human Pathology. vol.81, pp. 1-8, 2018.

. A. S. Singh, N.S. Chawla, & S. P. Chawla, “Giant-cell tumor of bone: treatment options and role of denosumab”. Biologics : targets & therapy, vol.9, pp. 69–74, 2015.

. X. Niu, et al., “Giant cell tumor of the extremity retrospective analysis of 621 Chinese patients from one institution”. J Bone Joint Surg Am, vol.94,no.5, pp. 461–7, 2012.

. K.C. Saikia, S.K. Bhuyan, M. Borgohain, S.P. Saikia, A. Bora, F. Ahmed, “Giant cell tumour of bone: an analysis of 139 Indian patients”. J Orthop Sci, vol.16, no.5, pp.581-8, 2011.

. N. Lujic, J.Sopta, R.Kovacevic, V.Stevanovic, R. Davidovic, “Recurrence of giant cell tumour of bone: role of p53, cyclin D1, β-catenin, and Ki67”. International Orthopaedics, vol. 40(11), pp.2393-2399, 2016.

. G.H. Prosser, K.G. Baloch, R.M. Tillman, S.R. Carter, R.J. Grimer,“Does curettage without adjuvant therapy provide low recurrence rates in giant cell tumours of bone?” Clin Orthop Relat Res, vol.435, pp. 211–8, 2005.

. A. Takeuchi, H. Tsuchiya, X. Niu, T.Ueda, D.G. Jeon, E.H. Wang, Y.K. Kang, “The prognostic factors of recurrent GCT: a cooperative study by the Eastern Asian Musculoskeletal Oncology Group”. J Orthop Sci, vol.16(2), pp.196-202, 2011.

. Y.H. Han, et al., “Expression of CD147, PCNA, VEGF, MMPs and their clinical significance in the giant cell tumor of bone of bones”. Int J Clin Exp Pathol, vol. 8(7), pp. 8446-8452, 2015.

. D.D. Cheng, T. Hu, H.Z. Zhang, J. Huang, J., & Q.C. Yang, “Factors Affecting the Recurrence of Giant cell tumor of bone of Bone After Surgery: A Clinicopathological Study of 80 Cases from a Single Center”. Cell Physiol Biochem, vol.36(5), pp. 1961-1970, 2015.

. X. Zhou, X.Z.Liu, G.T.Fan, S.J.Wu, J.N. Zhao, X. Shi, “Expression of Matrix Metalloproteinase-9 and CD34 in Giant Cell Tumor of Bone”. Orthopaedic Surgery, vol.8 (2), pp. 220–225, 2016.




How to Cite

Ameliah, A. ., A. Miskad, U. ., P. Johan, M. ., Sungowati, N. K. ., A. Zainuddin, A. ., & Achmad, D. . (2021). Clinical Characteristics for Predicting Recurrency in Giant Cell Tumor of Bone. International Journal of Sciences: Basic and Applied Research (IJSBAR), 60(1), 1–7. Retrieved from